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Background. Authors report clinical outcomes of patients treated with robotic stereotactic body radiotherapy (SBRT) 
for primary, recurrent and metastatic lung lesions.
Patients and methods. 130 patients with 160 lesions were treated with Cyberknife SBRT, including T1-3 primary 
lung cancers (54%), recurrent tumors (22%) and pulmonary metastases (24%). The mean biologically equivalent dose 
(BED10Gy) was 151 Gy (72–180 Gy). Median prescribed dose for peripheral and central lesions was 3x20 Gy and 3x15 Gy, 
respectively. Local control (LC), overall survival (OS), and cause-specific survival (CSS) rates, early and late toxicities 
are reported. Statistical analysis was performed to identify factors influencing local tumor control. 
Results. Median follow-up time was 21 months. In univariate analysis, higher dose was associated with better LC and 
a cut-off value was detected at BED10Gy ≤ 112.5 Gy, resulting in 1-, 2-, and 3-year actuarial LC rates of 93%, vs 73%, 80% 
vs 61%, and 63% vs 54%, for the high and low dose groups, respectively (p = 0.0061, HR = 0.384). In multivariate analy-
sis, metastatic origin, histological confirmation and larger Planning Target Volume (PTV) were associated with higher 
risk of local failure. Actuarial OS and CSS rates at 1, 2, and 3 years were 85%, 74% and 62%, and 93%, 89% and 80%, 
respectively. Acute and late toxicities ≥ Gr 3 were observed in 3 (2%) and 6 patients (5%), respectively.
Conclusions. Our favorable LC and survival rates after robotic SBRT, with low rates of severe toxicities, are coherent 
with the literature data in this mixed, non-selected study population.
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Introduction
Although surgical resection is considered as the 
standard of care in patients with early-stage non-
small cell lung cancer (NSCLC), a significant per-
centage of mostly elderly patients are not eligible 
for this treatment. Stereotactic body radiotherapy 
(SBRT) is considered to be an effective and well 
tolerated, non-invasive treatment option for this 
population.1,2 Efforts have already been made to 
directly compare the effectiveness and toxicity 
of SBRT to surgery for operable patients in rand-
Radiology and Oncology  |  Ljubljana  |  Slovenia  |  www.radioloncol.com
Authenticated | janvary.levente@med.unideb.hu author's copy
Download Date | 4/17/17 9:13 PM
Radiol Oncol 2017
Janvary ZL et al. / Outcomes of Cyberknife lung stereotactic body radiotherapy 2
omized trials, but unfortunately, these trials did 
not reach their accrual target and were prematurily 
closed because of low recruitment.2
However data from prospective trials show 
consistenly high levels of local control rates with 
stereotactic irradiation of early stage NSCLC.3-6 
Although SBRT literature is more extensive for 
early stage primary lung cancer, publications con-
cerning recurrent lung tumors and lung metastases 
also show high local control rates.7-9 On the basis of 
the published clinical experience stereotactic radio-
therapy of the lung became one of the most estab-
lished indications of SBRT.10-11 A clear dose-effect 
relationship has been shown by several SBRT stud-
ies, and a BED10Gy ≥ 100 Gy (Biologically Effective 
Dose with an α/β of 10 Gy) was found to be associ-
ated with better results.12 Nevertheless, the deliv-
ered dose and fraction number should be tailored 
to the anatomical situation and size of the lesion, as 
the proximity of critical organs can lead to higher 
probability of toxicity.
Although there have been attemps for single 
fraction treatments13-14, generally lung SBRT is de-
livered in 3 to 8 fractions. Treatment-related severe 
toxicities are uncommon using “risk-adapted” 
fractionation schemes with lower dose per fraction 
for central tumors.15 
The purpose of this study is to evaluate and re-
port the clinical outcomes of the first 130 consecu-
tively treated patients presented with primary, 
recurrent primary or secondary lung tumors. The 
primary objective was to analyse local therapeutic 
efficacy of robotic SBRT and factors influencing lo-
cal control. The secondary objectives were to evalu-
ate early and late toxicities and survival results.
Patients and methods
Patients
Cyberknife® (Accuray Inc. Sunnyvale, USA) ro-
botic SBRT treatments were started at the Liege 
University Hospital in April 2010. Ordinary indi-
cations for SBRT treatment include T1-T2 primary 
NSCLC, recurrent primary lung tumors, and soli-
tary-, or oligometastases. However, more rarely 
this treatment is appied on T3 tumors or soliter 
lymph node metastases.16-19 The majority of prima-
ry and recurrent lung tumors in our cohort were 
considered ineligible for surgical resection because 
of poor lung functions or severe comorbidities. For 
metastatic lesions medical inoperability; > 1 lesions 
in different lobes or lungs; prior lobectomy and 
patient preference were the major causes leading 
to the choice of SBRT. Based on individual medical 
consideration and absence of realistic therapeutic 
alternatives a small number of unusual indications 
were also included, like patients harboring T3N0 
or T1N1 disease. In the present study 130 consec-
utive patients treated with BED10Gy ≥ 72 Gy were 
evaluated. Central or large tumors were not ex-
cluded, but the dose and number of fractions were 
adapted. Central lesions were defined as lesions 
located whithin 2 cm from the pulmonary hilum, 
heart, great vessels, or trachea. Indications for each 
individual patient were discussed and approved 
in multi-disciplinary tumor boards. Especially for 
primary tumors, pathological confirmation was 
requested either by bronchofiberoscopy or tran-
sthoracic biopsy. For patients considered not eligi-
ble for histological confirmation (due to technical 
or medical reasons), the indication was based on 
strong clinical suspicion supported by positron 
emission tomography (PET).
One hundred and thirty patients, with a total of 
160 lung lesions were treated between April 2010 
and June 2012. Patient and tumor characteristics 
are listed in Table 1. 
TABLE 1. Patient, tumor and treatment characteristcs
Characteristic n (%)
Total number of patients/lesions 130 (100%)/160 (100%)
Mean age in years 71 (range: 40–92)
Male/female ratio 77 (59%) / 53 (41%) 
No. with COPD 45 (35%)
Mean FEV1 (%) 65 (range: 24–139)
Mean FEV1 (L) 2 (range: 0.53–3.65)
Histological confirmation 79 (61%)
Primary cancer patients/lesions 81 (62%) / 86 (54%)
    T1N0 53
    T2N0 19
    T3N0 5
    T1N1 4
Recurrent tumor patients /lesions (n) 23 (18%) / 35 (22%)
Lung metastasis patients /lesions (n) 26 (20%) / 39 (24%)
Mean GTV volume (ml) 11.5 (range: 0.6–86.5)
Mean PTV volume (ml) 33.2 (range: 5.8–118.1)
Location of lesions: peripheral/central 113 (71%) /47 (29%)
Mean total dose (Gy)/Mean no. of fractions 60/3 fx (range: 40–60 / 3–5 fx)
Mean/median BED10Gy (Gy) 151/180 Gy 
BED = mean biologically equivalent dose; COPD = chronic obstructive pulmonary disease; FEV1 = 
forced expiratory volume in 1 second; fx = fractions; GTV = gross tumour volume; PTV = planning 
target volume
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Median age of patients at treatment was 71 
years (range 40–93), and 59% (n = 77) were males. 
Distribution of lesions were: 53% (n = 86) primary, 
22% (n = 35) recurrent tumor/intrapulmonary me-
tastasis of a lung tumor and 25% (n = 39) metasta-
ses from other cancer. Cancer of origin for metasta-
tatic lesions were: colorectal (49%; n = 19), salivary 
gland (13%; n = 5), breast (10%; n = 4) , melanoma 
(5%; n = 2), kidney (5%; n = 2), neuroendocrin (3%; 
n = 1), multiple primary (13%; n = 5) , unkown 
(2%; n = 1). Distribution of histological types for 
the patient group with pathologically confirmed 
primary lung cancer was: 47% adenocarcinoma 
(n = 29), 33% squamosus cell carcinoma (n = 21), 
15% NSCLC (n = 9), 5% undifferentiated (n = 3). 
The maximal number of lesions treated by SBRT in 
the same patient was four. Four patients were pre-
sented with stage T1N1 disease. For these patients 
the affected lymph node(s) were also treated with 
SBRT. Positivity of these lymph nodes were based 
on high SUVmax value on PET CT, without cyto-
logical confirmation, but usually the histology of 
the belonging primary tumors were known.
One patient was categorized as T3 for tumor 
size, the other four T3 patients had mediastinal 
pleura invasion or separate nodule in the same 
lobe. 
Distribution of the 113 peripheral lesions was : 
n = 66 primary, n = 21 recurrent, n = 26 metastasis. 
The group of 47 central lesions was composed of 
17 primary tumors plus 3 synchronous N1 lymph 
nodes, 14 recurrent cancers and 13 metastases.
Treatment preparation
Technical characteristics and tracking options of 
the Cyberknife robotic SBRT system have been 
exhaustively detailed elsewhere.16-17 For thoracic 
tumors there are three different tracking types, 
which can be appropriately selected according to 
each clinical case. Synchrony® is a real-time tumor 
tracking algorithm which requires fiducial mark-
ers to be previously inserted inside or near to the 
target. The fiducials are detected by orthogonal 
X-rays at the treatment room. The system includes 
an infrared camera that monitors the movement of 
the chest. During treatment, spatial information on 
the location of the fiducials and data of the respira-
tory cycle are connected to redirect the robot, and 
realize real-time tracking. Fiducial insertion can be 
contraindicated for some patients because of the 
inherent risk of pneumothorax. For selected cases, 
when tumor silhouette is sharply identified on both 
ortogonal X-ray detector panels, the algorithm of 
Xsight Lung® can be used for tracking the target, 
without the need for implanted markers. When 
none of these two previously mentioned tracking 
algorithm is feasible, tracking is performed on the 
vertebra (XsightSpine®). 
Planning CT images were obtained with a slice 
thickness of 1 mm. Patients were immobilised us-
ing an individual vacuum bag ˝in supine position, 
with arms next to the body. Four-dimensional (4D) 
CT simulation was not introduced for Cyberknife 
treatment, thus expiration and moderate inspira-
tion CT scans were acquired to estimate magnitude 
of respiratory releated tumor movement. In case of 
fiducial-, or direct tumor tracking, only expiration 
CTs were used for delineation. For patients with 
fiducial markers, CT simulation was delayed with 
a minimum of 10 days after implantation to mini-
mise uncertainity linked to the potential marker 
migration.
The vast majority of patients (n = 125; 96%) had 
PET CT scans in treatment position using the same 
individual vacuum bag used at the CT simulation, 
to optimize target volume definition.
For patients with real-time tumor tracking gen-
erally a margin of 3 mm was applied around the 
gross tumor volume (GTV) to achieve clinical tar-
get volume (CTV). CTV contours were then, cor-
rected manually when overlapping with ribs or 
mediastinal structures. An additional 2 mm was 
added to create planning target volume (PTV).
When real time tumor tracking was not feasible, 
we used an internal target volume of GTV, large 
enough to cover all possible tumor positions dur-
ing the respiratory cycle. After that, the method 
and the margins for creating CTV-internal target 
volume (ITV) and PTV was similar to real time 
tracked patients. 
SBRT procedure
Treatment plans were implemented with Multiplan 
treatment planning system (TPS) version 5.1 
(Accuray Inc. Sunnyvale, USA), using Ray Tracing 
calculation algorythm. Prescription doses varied 
between 40 to 60 Gy in 3 to 5 fractions, depending 
on proximity to organs at risk (OAR) and on tu-
mor size. Dose was typically prescribed to the 80% 
isodose line (75–82%) encompassing the PTV. Dose 
constrains to OARs were applied according to a 
class solution (Table 2) which was based on pub-
lished data of Timmerman and AAPM Taskgroup 
101 guidelines.18-19 
SBRT treatments were performed by Cyberknife 
Robotic Radiosurgery treatment unit (Accuray Inc. 
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Sunnyvale, USA). Treatment consisted of typically 
100–200 non-coplanar beams using Iris® various 
aperture collimator in a range between 15 to 60 mm 
with a dose rate of 600 MU/min.
Follow up and toxicity evaluation
Patients were followed up by the treating radiation 
oncologist and/or by referring pulmonologist or 
oncologist. In addition to regular CT-scans, meta-
bolic follow up of treatment effect by PET CT was 
performed in 118 patients (91%) to make distinction 
between local disease progression and localized 
pulmonary fibrosis.20,21 Acute and late toxicities 
were evaluated using the Common Terminology 
Criteria for Adverse Events (CTCAE v4.0). Toxicity 
was classified as acute up to 3 months after SBRT.
The patient follow up time was defined as the 
period between the first day of Cyberknife treat-
ment to the date of last visit or death.
Statistical analysis
Patient and lesion characteristics and toxicities were 
described in terms of means or medians (range) or 
in terms of numbers (%). A descriptive analysis 
was used to present patient and treatment charac-
teristics and toxicity data. Local control (LC), over-
all survival (OS) and cause-specific survival (CSS) 
rates were estimated by the Kaplan-Meier method. 
The prognostic value of patient and tumor char-
acteristics on LC was determined using uni- and 
multivariate Cox regression models. Results were 
considered to be statisticallysignificant at p-values 
≤ 0.05. Statistical analysis was performed with the 
SAS version 9.3 software (SAS Institute, Cary, NC, 
USA).
Ethical considerations
This retrospective cohort study was approved by 
institutional review board. 
Results
The mean and median follow up time (FUP) was 21 
months (range 2–39) with only 8 cases (6.2%) with 
a follow-up of less than 6 months. Total dose and 
number of fractions was determined with consid-
eration of tumor location and size. In some cases 
the initially planned dose was reduced and/or the 
fraction number was increased in order to better 
meet OAR constraints. The applied dose and frac-
tionation schemes are described in Table 3. 
Delivered dose varied from BED10Gy = 72 Gy (40 
Gy in 5 fractions) to BED10Gy = 180 Gy (60 Gy in 3 
fractions). The median dose for peripheral lesions 
was 3x 20Gy, whereas for central lesions the me-
dian was 3x 15Gy. Mean/median BED10Gy for pe-
ripheral and central lesions were 170/180Gy and 
102/112.5 Gy, respectively. Real-time tumor track-
ing was performed in 42% of treatments (n = 66) 
either using gold fiducial based (Synchrony) or di-
rect fluoroscopic (Xsight Lung) methods.
Local control
For the whole cohort the actuarial 1-, 2-, and 3-year 
LC rates were 86%, 75%, and 62%, respectively.
In univariate Cox regression model, a higher 
BED10Gy was associated with better LC (p = 0.008). 
Analysis of the different dose levels found a cut-
off value between BED 112.5 Gy and 132 Gy. 
Treatments using doses higher than 112.5 Gy 
TABLE 2. Dose constraints for organs at risk 
Organ Type of constraint
Dose (Gy) for 
3 fractions SBRT 
Dose (Gy) for 
5 fractions SBRT
Spinal cord Dmax 22 (7.33 Gy/fx) 30 (6 Gy/fx)
Esophagus Dmax 27 (9 Gy/fx) 35 (7 Gy/fx)
Trachea and main 
bronchi Dmax 30 (10 Gy/fx) 32 (6.4 Gy/fx)
Heart Dmax 30 (10 Gy/fx) 38 (7.6 Gy/fx)
Plexus brachialis Dmax 24 (8 Gy/fx) 32 (6.4 Gy/fx)
Ribs Dmax 37 (12.3/fx) 43 (8.6/fx)
Skin Dmax 32 (10.6/fx) 24 (4.8/fx)
Lung (both lungs) Volumetric V10.5Gy < 1500 ccV11.4Gy < 1000 cc
V12.5Gy < 1500 cc
V13.5Gy < 1000 cc
Liver Volumetric V17.1Gy < 700 cc V21Gy < 700 cc
TABLE 3. Dose-fractionation schemes
Radiotherapy 
scheme BED10Gy (Gy) n (%)
3x20 Gy 180 96 (60%)
3x18 Gy 151.2 7 (4%)
3x17 Gy 137.7 4 (2.5%)
5x12 Gy 132 1 (0,6%)
3x15 Gy 112.5 24 (15%)
5x10 Gy 100 4 (2.5%)
5x9 Gy 85.5 11 (7%)
5x8 Gy 72 13 (8%)
BED = mean biologically equivalent dose
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showed a significant advantage in terms of LC, re-
sulting 1-, 2-, and 3-year actuarial LC rates of 93% 
vs 73%, 80% vs 61%, and 63% vs 54%, respectively 
(p = 0.0061, HR = 0.384; Figure 1).
In univariate analysis there were no significant 
differences between primary (P), recurrent (R) and 
metastatic (M) lesions in terms of actuarial LC (p = 
0.091). However in pairwise comparison primary 
tumors provided improved results compared to 
metastases: 1-, 2-, and 3-year LC rates were 89% vs 
84%, 80% vs 59%, and 64% vs 53%, respectively (p = 
0.035; Figure 2). Other factors such as tumor track-
ing (inclusive tracking modality), and histological 
confirmation of malignancy had no significant ef-
fect on LC.
During separate analysis of the primary tumor 
group there was no significant difference in LC 
according to T-stage. However, there was a a non-
significant trend favoring LC in T1 compared to T2 
(p = 0.063). 
Local control was significantly higher for pe-
ripheral lesions, compared to central lesions (p = 
0.025), resulting in 1-, 2-, and 3-year LC rates of 
91% vs 74%, 79% vs 63%, and 60% vs 56%, respec-
tively (Figure 3).
In univariate Cox regression model, larger GTV 
and PTV volumes were associated with a higher 
risk of local relapse (p = 0.0034 and p = 0.0013, re-
spectively).
The variables tested in multivariate analysis were 
tumor type (primary/recurrent/metastasis), track-
ing (yes/no), confirmed histology (yes/no), location 
of lesions (central/peripheral), BED10Gy, GTV, PTV, 
and PTV coverage. These variables were selected 
in order to determine treatment and tumor factors 
influencing LC. In multivariate analysis the meta-
static origin of lesions (HR = 7.3; p < 0.0001), the his-
tological confirmation of malignancy (HR = 4.1; p = 
0.0052) and larger PTV (HR = 1.03; p < 0.0001) were 
associated with significantly lower LC rate.
Overall survival and cause-specific 
survival 
One-, two-, and three-year actuarial rates of OS 
were 85%, 74% and 62%, respetively, whereas the 
respective rates of CSS were 93%, 90%, and 80%.
Early and late toxicities
Treatment related Grade (G) 3 or higher acute and 
late toxicities were observed at 3 (2%) and 6 patients 
(5%), respectively. Acute toxicities included 2 cases 
(1.5%) of G3 pneumonitis and a single case (0.8%) of 
FIGURE 1. Probabilty of local control according to dose (BED ≤ 112.5 Gy vs. higher).
FIGURE 3. Probability of local control for peripheral (n = 113) and central (n = 47) 
lesions.
FIGURE 2. Probability of local control for primary (n = 86), recurrent (n = 35) and 
metastatic (n = 39) lesions. 
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G5 pulmonary haemorrhage. This latter elderly (85 
years old) patient had a fatal ipsilateral pulmonary 
haemorrhage 1 month after the completion of his 
SBRT (45 Gy in 5 fractions) for a right sided central 
tumor recurrence, and was classified as a possible 
treatment related adverse event. The patient had al-
ready been treated with chemotherapy 4 years ear-
lier for his primary lung tumor, and 1 year earlier 
by Cyberknife for a contralateral upper lobe relapse 
without progression until the time of death.
Late toxicities were G3 dyspnea (n = 3; 2.3%, 
all presenting with chronic obstructive pulmo-
nary disease [COPD] Global Initiative for Chronic 
Obstructive Lung Disease [GOLD] III prior to 
SBRT), G3 sick sinus syndrome (n = 1; 0.8%) requir-
ing pacemaker implantation 8 months after SBRT, 
G3 pain due to a rib fracture requiring major an-
algesic (n = 1; 0.8%). One patient (0.8%) suffered 
a fatal haemorrhage (G5) 7 months after SBRT for 
a centrally located recurrent tumor mass, which 
invaded vascular structures already at the time 
of detection, and had shown progression after 
Cyberknife treatment (40 Gy in 5 fracions). This 
case was encoded as a treatment related adverse 
event, although local tumor progression could not 
be formally excluded.
Grade 2 late toxicities were also recorded such as 
asymptomatic or moderately painful rib fractures 
(n = 5; 3.8%), recurrent laryngeal nerve palsy (n = 
1; 0.8%), late radiation pneumonitis (n = 14; 10.8%) 
and pneumothorax (n = 6; 4.6%) after transthoracic 
marker placement requiring tube placement for a 
few days.
Discussion
High (86%, 75%, and 62% at 1, 2, and 3 years) actu-
arial LC rates were observed at the first 130 consec-
utive patients treated with lung SBRT in our insti-
tution. Our results are comparable with published 
data from other lung SBRT series (Table 4).4-5,7-9, 22-28 
Bahig et al. reported their results on 150 patients 
treated with Cyberknife with a median dose of 60 
TABLE 4. Comparative table of relevant published data and own results
Study Technic
Histological 
confirmation 
%
No. of 
pts/
lesions
dose (Gy)/fx BED10Gy (Gray)
Median 
FUP 
(month)
Local Control Overall Survival
PRIMARY
Chen VJ (26) CK 100 40 median 48 (42-60)/3 fx 124.8 44 91%@3y 75%@3y
van der Voort
van Zyp (27) CK 51 70 
60/3fx (Peripheral)
45/3fx (Central)
180 (Peripheral)
112.5 (Central) 15
96%@2y for 60 Gy
78%@2y for 45 Gy 62%@2y 
Factor (28) CK 95 78 60/3 fx (Peripheral)48/4 fx (Central) 75-180 14.4 87%@2y 68%@2y 
Bahig (4) CK 84 150 median 60/3 fx40- 60/3-5 fx
72-180 (Peripheral)
106-180 (Central) 22 96%@2y 87%@2y
Shen (29) CK 84 50 57 (48-60)/3fx 104-150 35 crude 96%@2y 86%@1y74%@2y
Davis, RSS REGISTRY (5) CK,LINAC 100 723/741 median 54 (10-80)/3 fx 151.2 12 
88%@1y 
76%@2y 
T1: 85/63%@1/2y
T2: 76/52@1y/2y
Fakiris (30) LINAC 100 70 60-66/3fx 180-211.2 50.2 88.1%@3y 42.7%@3y 
METASTASES
Nuyttens (7) CK 12 30/57 30/1 fx; 60/3-5 fx; 56/7 fx 36 79%@1y 63%@2y38%@4y
Inoue (8) LINAC 87/189 48/3fx; 50/5 fx; 52-60/10 fx; 30-168 80%@2y80%@3y
47%@2y
32%%@3y
MIXED: PRIMARY+METASTASES
Guckenberger (31) LINAC 19 124/159 26/1 fx; 37.5/3; 48/8 fx 14 83%@3y 37%@3y (Primary) 16%@3y (Met)
Ernst-Stecken (9) LINAC 100 21/39 35-40/5 fx 59.5-72 6.3 crude: 87% crude: 86%
Duncker-Rohr (32) LINAC 55 39/45  37.5/3 fx; 30/5 fx 84 (Peripheral)60 (Central) 17
80.5%@2y
95% @2y Prim
59.7%@2y Met
52.7%@2y
45.9% (Primary)
66.7% (Met)
Current study CK total 61%primary 77% 130/160
median 60/3 fx (Peripheral)
median 45/5 fx (Central)
median 180 (Peripheral)
median 112.5 (Central) 21 
86%@1y
75%@2y 
62 %@3y
BED = mean biologically equivalent dose; CK = Cyberknife; fx = fractions; LINAC = linear accelerator, Met = metastases; Prim = primary tumour; Y = year
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Gy in 3 fractions leading to exellent LC rates of 
96% at 2 years. This cohort, including peripheral 
and central tumors, consisted of purely stage T1-2 
primary NSCLC.4 In our study favorable LC was 
observed for primary tumors compared to meta-
static lesions. The same finding was reported by 
Duncken-Rohr32, while Guckenberger et al.31n = 
41; Stage IA, n = 13; Stage IB, n = 19; T3N0, n = 9 
showed comparable 3-year results for primary and 
metastatic lesions treated with SBRT between the 
two groups at 3 years. In a comparative study of 
primary and metastatic lung tumors by Yamamoto 
et al.33 tumor diameter and metastatic origin were 
associated with significantly lower LC rates, which 
is congruent with our findings.
Location of the target in lung SBRT has an im-
portant role in defining maximum deliverable 
doses in function of their proximity to adjacent ra-
diosensitive OARS. In our analysis, LC rates at 1-, 
2-, and 3-years are significantly different between 
central and peripheral lesions. The same observa-
tion was reported by van der Voort van Zyp et al. 
with LC of 96 % vs.78% LC at 2 years for peripheral 
vs. central T1-2 NSCLC lung tumors treated with 
60 Gy or 45 Gy in 3 fractions, respectively.27
The question of optimal dose of SBRT for cen-
tral lesions remains unclear however, careful and 
appropriate dose-fractionation can lead to high tu-
mor control with low rate of severe toxicities even 
in this population. In our series the overall mean 
BED10Gy was 151 Gy with a range between 72–180 
Gy. As the total dose and the number of fractions 
was determined by the location and the size of the 
target lesion, the same treatment schedules were 
applied for primary, recurrent and metastatic le-
sions. Central lesions were treated with a mean /
median BED10Gy of 102/112.5 Gy, the correspond-
ing doses for peripheral lesions were 170/180 Gy, 
respectively. Obviously, the above seen better local 
control rates for peripheral tumors were linked to 
higher deliverable dose.
In a recent systematic review of central tumors 
Senthi et al.34 have found that LC rates ≥ 85 % can 
be achieved with low rates of complications when 
prescribed BED on the tumor is ≥ 100Gy, and at the 
same time the biologically equivalent normal tissue 
dose does not exceed 210 Gy. In a recent multicen-
tric analysis of linac based central lung SBRT for 
NSCLC in German and Austrian institutions,the 
authors show similar LC rates to ours with 76%, 
64% and 52% at 1, 2, and 3 years with a delivered 
median BED10 of 72 Gy (range 43–180 Gy).35 
In series reporting results of purely peripheral, 
T1-2 NSCLC treated with similar technology and 
doses to ours, LC rates as high as 83.8–100% were 
achieved at 2 years.26,29,36-38 
A subgroup analysis of primary lung cancer 
patients in our cohort yielded actuarial 1-, 2-, and 
3-year LC of 89%, 80%, and 64 %, respectively. 
These results are similar to the findings of a recent, 
large scale publication on data of the RSSearch® 
Patient Registry of Radiosurgery Society report-
ing the clinical outcome of 723 patients with early 
stage, node negative NSCLC treated with various 
SBRT techniques achieving 88% and 76% LC rates 
at 1 and 2 years, respectively.5 
For metastatic and recurrent patient groups we 
observed 1-, 2-, and 3-year LC rates of 84%, 59%, 
53% and 83%, 83%, 83%, respectively. Inoue et al.8 
reported comparable results (3-year LC rate of 
80%) in a large cohort study of central and periph-
eral metastases of 87 pts (189 lesions). 
Although the distribition of patient numbers 
at the different dose-levels was particularly inbal-
anced in our cohort, analysis was performed on ef-
fect of BED10Gy on LC. A clear correlation between 
the applied dose and the actuarial local control 
rates were found with a cut-off at BED10Gy of 112.5 
Gy, where lower doses were associated with high-
er rates of local recurrence. Local control rates at 1, 
2, and 3 years were 93% vs 73%, 80% vs 61%, and 
63% vs 54%, for the higher and lower dose groups, 
respectively (p = 0.0061, HR = 0.384). These results 
are coherent with the findings of others, however 
dose cut-off was found to be somewhat lower in 
the literature. Onishi et al.12 and Olsen et al.39 has 
shown that SBRT with a BED10Gy ≥ 100 Gy was as-
sociated with significantly better LC rates than 
those with lower doses. In a large cohort study 
of 505 patients treated for NSCLC BED10Gy < 105 
Gy predicted higher local recurrence rates of 15% 
vs 4% in the low dose and high dose group, re-
spectively.40 In contrast, in a cohort of 94 NSCLC 
Stephans et al.41 did not observe a significant differ-
ence in 12 months actuarial LC between fractiona-
tion schemes of 5x10 Gy vs 3x20 Gy (BED10Gy = 100 
Gy vs 180Gy).
The limitations of our findings concerning the 
optimal BED10Gy include the inbalanced distribu-
tion of patients in different dose-level groups, the 
possible selection bias and the non-randomized na-
ture of this cohort study.
The incidence of G3 or higher toxities in our 
study was coherent with the literature with 2% of 
acute and 5% of late complications.8,38 Two patients 
out of 130 (1.5%) has died because of pulmonary 
haemorrhage. Grade 5 toxicities are rare, but exist-
ing complications of SBRT, occuring predominant-
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ly in centrally located tumors with an incidence 
of 0–2% in the literature.4,35 This low incidence of 
treatment realted deaths can reasonably be con-
sidered as acceptable, given the lack of treatment 
alternatives for this population.
Conclusions
Stereotactic ablative radiotherapy using the 
CybeKnife system for the treatment of primary, 
recurrent and metastatic lung lesions seems to be 
a safe and effective treatment option for medically 
inoperable patients. A clear dose-response relation-
ship was confirmed with a significantly improved 
local control with BED10Gy over 112.5 Gy. More firm 
data from prospective trials are needed to validate 
findings of this study.
References
1.  van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, Pattynama P, 
Maat A, Nuyttens JJ. Stereotactic body radiotherapy using real-time tumor 
tracking in octogenarians with non-small cell lung cancer. Lung Cancer 2010; 
69: 296-301. doi: 10.1016/j.lungcan.2009.12.008
2.  Chang JY, Senan S, Paul MA, Mehran RJ, Louie A V, Groen HJM, et al. 
Stereotactic ablative radiotherapy versus lobectomy for operable stage 
I non-small-cell lung cancer: a pooled analysis of two randomised trials. 
Lancet Oncol 2016; 16: 630-7. doi: 10.1016/S1470-2045(15)70168-3
3.  Videtic GMM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser E, et al. 
Intensity-modulated radiotherapy-based stereotactic body radiotherapy for 
medically inoperable early-stage lung cancer: excellent local control. Int J 
Radiat Oncol Biol Phys 2010; 77: 344-9. doi: 10.1016/j.ijrobp.2009.05.004
4.  Bahig H, Filion E, Vu T, Roberge D, Lambert L, Bouchard M, et al. Excellent 
cancer outcomes following patient-adapted robotic lung SBRT but a case for 
caution in idiopathic pulmonary fibrosis. Technol Cancer Res Treat 2015; 14: 
667-76. doi: 10.7785/tcrt.2012.500445
5.  Davis JN, Medbery C, Sharma S, Perry D, Pablo J, D’Ambrosio DJ, et al. 
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: 
clinical outcomes from a National Patient Registry. J Radiat Oncol 2015; 4: 
55-63. doi: 10.1007/s13566-014-0177-0
6.  Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. 
Outcome in a prospective phase II trial of medically inoperable stage I non-
small-cell lung cancer patients treated with stereotactic body radiotherapy. 
J Clin Oncol 2009; 27: 3290-6. doi: 10.1200/JCO.2008.21.5681
7.  Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, Maat A, van Klaveren RJ, 
van der Holt B, et al. Stereotactic body radiation therapy for oligometastases 
to the lung: a Phase 2 Study. Int J Radiat Oncol Biol Phys 2015; 91: 337-43. 
doi: 10.1016/j.ijrobp.2014.10.021
8.  Inoue T, Oh R-J, Shiomi H, Masai N, Miura H. Stereotactic body radiother-
apy for pulmonary metastases. Prognostic factors and adverse respiratory 
events. Strahlenther Onkol 2013; 189: 285-92. doi: 10.1007/s00066-012-
0290-1
9.  Ernst-Stecken A, Lambrecht U, Mueller R, Sauer R, Grabenbauer G. 
Hypofractionated stereotactic radiotherapy for primary and secondary 
intrapulmonary tumors: First results of a phase I/II study. Strahlenther Onkol 
2006; 182: 696-702. doi: 10.1007/s00066-006-1577-x
10.  De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price 
A, et al. European Organisation for Research and Treatment of Cancer 
recommendations for planning and delivery of high-dose, high-precision 
radiotherapy for lung cancer. J Clin Oncol 2010; 28: 5301-10. doi: 10.1200/
JCO.2010.30.3271
11.  Vansteenkiste J, De Ruysscher D, Eberhardt WEE, Lim E, Senan S, Felip E, 
et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann 
Oncol 2013; 24(Suppl 6): vi89-98. doi: 10.1093/annonc/mdt241
12.  Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. 
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-
small cell lung cancer: updated results of 257 patients in a Japanese 
multi-institutional study. J Thorac Oncol 2007; 2(7 Suppl 3): S94-100. doi: 
10.1097/JTO.0b013e318074de34
13.  Hof H, Herfarth KK, Münter M, Hoess A, Motsch J, Wannenmacher M, et al. 
Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer 
(NSCLC). Int J Radiat Oncol Biol Phys 2003; 56: 335-41. doi: 10.1016/S0360-
3016(02)04504-2
14.  Hof H, Hoess A, Oetzel D, Debus J, Herfarth K. Stereotactic single-dose 
radiotherapy of lung metastases. Strahlenther Onkol 2007; 183: 673-8. doi: 
10.1007/s00066-007-1724-z
15.  Senan S, Lagerwaard F. Stereotactic radiotherapy for stage I lung cancer: 
current results and new developments. Cancer Radiother 2010; 14: 115-8. 
doi: 10.1016/j.canrad.2009.11.003
16.  Chen Y, Guo W, Lu Y, Zou B. Dose-individualized stereotactic body radiother-
apy for T1-3N0 non-small cell lung cancer: Long-term results and efficacy of 
adjuvant chemotherapy. Radiother Oncol 2008; 88: 351-8. doi: 10.1016/j.
radonc.2008.07.013
17.  Berriochoa C, Videtic GMM, Woody NM, Djemil T, Zhuang T, Stephans KL. 
Stereotactic body radiotherapy for T3N0 lung cancer with chest wall inva-
sion. Clin Lung Cancer 2016; 17: 595-601. doi: 10.1016/j.cllc.2016.04.007
18.  Jereczek-Fossa BA, Ronchi S, Orecchia R. Is stereotactic body radiotherapy 
(SBRT) in lymph node oligometastatic patients feasible and effective? Rep 
Pract Oncol Radiother 2015; 20: 472-83. doi: 10.1016/j.rpor.2014.10.004
19.  Meng M, Wang H, Zaorsky NG, Zhao X, Wu Q, Jiang B, et al. Clinical evalua-
tion of stereotactic radiation therapy for recurrent or second primary medi-
astinal lymph node metastases originating from non-small cell lung cancer. 
Oncotarget 2015; 6: 15690-703. doi: 10.18632/oncotarget.3704
20.  Gibbs IC. Frameless image-guided intracranial and extracranial radiosurgery 
using the Cyberknife robotic system. Cancer Radiother 2006; 10: 283-7. doi: 
10.1016/j.canrad.2006.05.013
21.  Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer CR. The CyberKnife robotic 
radiosurgery system in 2010. Technol Cancer Res Treat 2010; 9: 433-52. doi: 
10.1177/153303461000900502
22.  Timmerman RD. An overview of hypofractionation and introduction to this 
issue of Seminars in Radiation Oncology. Semin Radiat Oncol 2008; 18: 215-
22. doi: 10.1016/j.semradonc.2008.04.001
23.  Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. 
Stereotactic body radiation therapy: the report of AAPM Task Group 101. 
Med Phys 2010; 37: 4078-101. doi: 10.1118/1.3438081
24.  Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. 
Pulmonary injury and tumor response after stereotactic body radiotherapy 
(SBRT): results of a serial follow-up CT study. Radiother Oncol 2007; 85: 435-
42. doi: 10.1016/j.radonc.2007.10.044
25.  Essler M, Wantke J, Mayer B, Scheidhauer K, Bundschuh RA, Haller B, et 
al. Positron-emission tomography CT to identify local recurrence in stage 
I lung cancer patients 1 year after stereotactic body radiation therapy. 
Strahlenther Onkol 2013; 189: 495-501. doi: 10.1007/s00066-013-0310-9
26.  Chen VJ, Oermann E, Vahdat S, Rabin J, Suy S, Yu X, et al. CyberKnife with 
tumor tracking: an effective treatment for high-risk surgical patients with 
stage I non-small cell lung cancer. Front Oncol 2012; 2: 1-5. doi: 10.3389/
fonc.2012.00009
27.  van der Voort van Zyp NC, Prévost J-B, Hoogeman MS, Praag J, van der Holt 
B, Levendag PC, et al. Stereotactic radiotherapy with real-time tumor track-
ing for non-small cell lung cancer: clinical outcome. Radiother Oncol 2009; 
91: 296-300. doi: 10.1016/j.radonc.2009.02.011
28.  Factor OB, Vu CC, Schneider JG, Witten MR, Schubach SL, Gittleman AE, 
et al. Stereotactic body radiation therapy for stage I non-small cell lung 
cancer: a small academic hospital experience. Front Oncol 2014; 4: 1-5. doi: 
10.3389/fonc.2014.00287
29.  Shen Z-T, Wu X-H, Li B, Zhu X-X. Clinical outcomes of CyberKnife stereotactic 
body radiotherapy for peripheral stage I non-small cell lung cancer. Med 
Oncol 2015; 32: 1-8. doi: 10.1007/s12032-015-0506-1
Authenticated | janvary.levente@med.unideb.hu author's copy
Download Date | 4/17/17 9:13 PM
Radiol Oncol 2017
Janvary ZL et al. / Outcomes of Cyberknife lung stereotactic body radiotherapy 9
30.  Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson M 
A, et al. Stereotactic body radiation therapy for early-stage non-small-cell 
lung carcinoma: four-year results of a prospective phase II Study. Int J Radiat 
Oncol Biol Phys 2009; 75: 677-82. doi: 10.1016/j.ijrobp.2008.11.042
31.  Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al. Dose-
response relationship for image-guided stereotactic body radiotherapy of 
pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol 
Phys 2009; 74: 47-54. doi: 10.1016/j.ijrobp.2008.06.1939
32.  Duncker-Rohr V, Nestle U, Momm F, Prokic V, Heinemann F, Mix M, et al. 
Stereotactic ablative radiotherapy for small lung tumors with a moderate 
dose: Favorable results and low toxicity. Strahlenther Onkol 2013; 189: 33-
40. doi: 10.1007/s00066-012-0224-y
33.  Yamamoto T, Jingu K, Shirata Y, Koto M, Matsushita H, Sugawara T, et al. 
Outcomes after stereotactic body radiotherapy for lung tumors, with em-
phasis on comparison of primary lung cancer and metastatic lung tumors. 
BMC Cancer 2014; 14: 464. doi: 10.1186/1471-2407-14-464
34.  Senthi S, Haasbeek CJ a, Slotman BJ, Senan S. Outcomes of stereotactic abla-
tive radiotherapy for central lung tumours: A systematic review. Radiother 
Oncol 2013; 106: 276-82. doi: 10.1016/j.radonc.2013.01.004
35.  Schanne DH, Nestle U, Allgäuer M, Andratschke N, Appold S, Dieckmann U, 
et al. Stereotactic body radiotherapy for centrally located stage I NSCLC: a 
multicenter analysis. Strahlenther Onkol 2014; 191: 125-32. doi: 10.1007/
s00066-014-0739-5
36.  Brown WT, Wu X, Fayad F, Fowler JF, García S, Monterroso MI, et al. 
Application of robotic stereotactic radiotherapy to peripheral stage I non-
small cell lung cancer with curative intent. Clin Oncol 2009; 21: 623-31. doi: 
10.1016/j.clon.2009.06.006
37.  Collins BT, Vahdat S, Erickson K, Collins SP, Suy S, Yu X, et al. Radical cy-
berknife radiosurgery with tumor tracking: an effective treatment for inop-
erable small peripheral stage I non-small cell lung cancer. J Hematol Oncol 
2009; 2: 1. doi: 10.1186/1756-8722-2-1
38.  Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, et al. 
CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 
18F-fluorodeoxyglucose positron emission tomography/computed tomog-
raphy serial tumor response assessment. J Hematol Oncol 2010; 3: 6. doi: 
10.1186/1756-8722-3-6
39.  Olsen JR, Robinson CG, El Naqa I, Creach KM, Drzymala RE, Bloch C, et 
al. Dose-response for stereotactic body radiotherapy in early-stage non-
small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 81: 299-303. doi: 
10.1016/j.ijrobp.2011.01.038
40.  Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, 
et al. A collaborative analysis of stereotactic lung radiotherapy outcomes 
for early-stage non–small-cell lung cancer using daily online cone-beam 
computed tomography image-guided radiotherapy. J Thorac Oncol 2012; 7: 
1382-93. doi: 10.1097/JTO.0b013e318260e00d
41.  Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, et al. 
A comparison of two stereotactic body radiation fractionation sched-
ules for medically inoperable stage I non-small cell lung cancer: the 
Cleveland Clinic experience. J Thorac Oncol 2009; 4: 976-82. doi: 10.1097/
JTO.0b013e3181adf509
Authenticated | janvary.levente@med.unideb.hu author's copy
Download Date | 4/17/17 9:13 PM
